More than an accessory: Implications of type III transforming growth factor-β receptor loss in prostate cancer

BJU International

Volumn 105, Issue 7, 2010, Pages 913-916

  Ajiboye, Seun ^a   Sissung, Tristan M ^a   Sharifi, Nima ^b   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Betaglycan; Prostate cancer; Testosterone; TGF III receptor

Indexed keywords

ACTIVIN; FOLLITROPIN; GROWTH FACTOR; INHIBIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ANGIOGENESIS; CANCER GROWTH; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR GROWTH;

DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TESTOSTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 77749290000     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08999.x     Document Type: Short Survey

References (21)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Kolesar JM. Prostate cancer. In Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Pharmacotherapy: a Pathophysiologic Approach, 7th edn, Chapter 134. New York : McGraw-Hill Companies, 2008 : 2207 2218
3. Turley RS, Finger EC, Hempel N et al. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007 67 : 1090 1098
4. Sharifi N, Lechleider RJ, Farrar WL. Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate? J Mol Endocrinol 2007 39 : 329 332
5. Wiater E, Lewis KA, Donaldson C et al. Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes. Mol Endocrinol 2009 23 : 1033 1042
6. Blobe GC, Schiemann WP, Pepin MC et al. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem 2001 276 : 24627 24637
7. Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 2009 106 : 8221 8226
8. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993 73 : 1435 1444
9. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005 23 : 2078 2093
10. Bandyopadhyay A, Wang L, Lopez-Casillas F et al. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 2005 63 : 81 90
11. Andres JL, DeFalcis D, Noda M, Massague J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 1992 267 : 5927 5930
12. Gregory SJ, Kaiser UB. Regulation of gonadotropins by inhibin and activin. Semin Reprod Med 2004 22 : 253 267
13. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003 113 : 685 700
14. Simon DP, Vadakkadath Meethal S, Wilson AC et al. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Neoplasia 2009 11 : 365 376
15. Kang HY, Huang HY, Hsieh CY et al. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. J Bone Miner Res 2009 24 : 1180 1193
16. Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and other tumors. Endocr Rev 2001 22 : 836 858
17. Sharifi N, Hurt EM, Kawasaki BT, Farrar WL. TGFβR3 loss and consequences in prostate cancer. Prostate 2007 67 : 301 311
18. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005 294 : 238 244
19. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 1994 135 : 2240 2247
20. Dowling CR, Risbridger GP. The role of inhibins and activins in prostate cancer pathogenesis. Endocr Relat Cancer 2000 7 : 243 256
21. Risbridger GP, Mellor SL, McPherson SJ, Schmitt JF. The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol 2001 180 : 149 153